DPG Media and Mediahuis fined for hidden advertising regarding Ozempic
The Dutch regulator has imposed a fine on media companies DPG Media and Mediahuis. The reason for this is that they published articles about the drug Ozempic that contained advertising not clearly recognizable as such. This is in violation of the rules regarding journalistic independence and consumer protection.
Ozempic is a drug originally intended for people with diabetes, but it is also widely used as a weight-loss aid. Because the drug is very popular, various newspapers and websites owned by the media companies wrote extensive articles about the product. According to the regulator, some of these texts resembled promotion more than independent journalism.
In the Netherlands, it is prohibited to advertise prescription drugs. The regulator states that the media companies blurred the line between editorial content and commercial messages. By failing to clearly mark the articles as 'advertisement' or 'sponsored content,' readers were misled about the nature of the information.
Both media companies have since responded to the ruling. They have indicated that they will better adhere to the guidelines in the future to ensure transparency for their readers. The fines are intended to serve as a warning to the entire media industry to handle commercial collaborations with greater care.
This case highlights how important it is for news media to safeguard their independence. For readers, it remains essential to look critically at the source of information, especially when it concerns health and medical products.